Last updated: October 5, 2026
Carbaglu, the brand name for carglumic acid, is an ultra-orphan metabolic medicine used to treat hyperammonemia caused by N-acetylglutamate synthase deficiency and certain organic acidemias. Its commercial profile is defined by a very small patient population, high treatment value, limited therapeutic substitution, and concentrated specialist distribution. Recordati owns the principal commercial rights through its rare-disease platform, while standalone Carbaglu revenue is not separately reported in public financial statements.
The product has a durable clinical position in NAGS deficiency, but its original U.S. regulatory exclusivity has expired. Future erosion risk is more likely to come from generic carglumic acid, hospital formulary substitution, and price pressure than from biosimilars. Because carglumic acid is a small molecule, biosimilar regulation does not apply.
What is Carbaglu and how large is its addressable market?
Carbaglu contains carglumic acid, a synthetic structural analog of N-acetylglutamate. It activates carbamoyl phosphate synthetase I, restoring the first step of the urea cycle in patients with NAGS deficiency. The product is also used to reduce ammonia levels in patients with propionic acidemia and methylmalonic acidemia.
| Attribute |
Carbaglu |
| Active ingredient |
Carglumic acid |
| Dosage form |
Dispersible tablets for oral suspension |
| U.S. sponsor |
Recordati Rare Diseases Inc. |
| Principal U.S. regulatory pathway |
505(b)(1) NDA |
| Original U.S. approval |
2010 |
| Key indications |
NAGS deficiency; hyperammonemia associated with propionic acidemia and methylmalonic acidemia |
| Therapeutic category |
Inborn errors of metabolism; nitrogen-scavenging therapy |
| Patient population |
Ultra-rare NAGS deficiency plus a broader organic-acidemia population |
| Commercial channel |
Specialty pharmacy, metabolic centers, hospitals, and rare-disease distributors |
NAGS deficiency is one of the rarest urea-cycle disorders. The organic-acidemia indication expands the potential population, although treatment is often episodic or linked to acute metabolic decompensation rather than continuous lifelong use.
The addressable market therefore has two different revenue pools:
- Lifelong or long-term treatment for confirmed NAGS deficiency.
- Acute or recurrent management of hyperammonemia in organic acidemias.
The first pool supports predictable recurring revenue. The second creates volume expansion but can produce more variable utilization.
When did Carbaglu receive FDA approval?
The FDA approved Carbaglu in March 2010 for acute and chronic treatment of hyperammonemia due to NAGS deficiency. FDA later approved the product for hyperammonemia associated with propionic acidemia and methylmalonic acidemia. The expanded indication increased the product's clinical reach beyond the original ultra-orphan population.
FDA regulatory milestones
| Milestone |
Date or status |
| FDA approval for NAGS deficiency |
2010 |
| Orphan-drug exclusivity for original indication |
Seven years from approval, generally ending in 2017 |
| FDA approval for organic acidemias |
Later supplemental approval |
| Current regulatory status |
Approved U.S. product |
| Pediatric exclusivity |
Any applicable pediatric period must be confirmed through current FDA regulatory records |
| Biosimilar pathway |
Not applicable because carglumic acid is a small molecule |
The original orphan exclusivity period protected the NAGS deficiency indication, but it did not create permanent market protection. Patent rights, regulatory exclusivity, and reimbursement barriers now carry more weight than orphan exclusivity.
Sources: FDA Drugs@FDA; FDA prescribing information; FDA Orphan Drug Designations and Approvals database.
What patents protect Carbaglu?
Carbaglu's current protection is weaker than the protection typically associated with recently launched specialty medicines. The principal active ingredient is a small molecule with an older scientific and regulatory history. The original composition-of-matter patent estate is not generally viewed as the primary commercial barrier today.
Patent categories relevant to carglumic acid
| Patent category |
Commercial relevance |
| Carglumic acid composition patents |
Likely expired or commercially weak in the United States |
| Manufacturing patents |
May protect process efficiency, purity, or scale-up |
| Tablet or dispersible formulation patents |
Could delay or complicate generic matching if active |
| Method-of-use patents |
Potentially relevant to organic-acidemia dosing or patient selection |
| Regulatory exclusivity |
Original U.S. orphan exclusivity expired |
| Trade secrets |
May protect manufacturing know-how and supply-chain controls |
A complete current patent determination requires review of the FDA Orange Book, USPTO records, assignment history, terminal disclaimers, and litigation docket. Public commercial information does not establish a broad, enforceable patent barrier comparable to those surrounding newer rare-disease drugs.
The most relevant protection risk is formulation and manufacturing equivalence. Carbaglu is not a conventional immediate-release tablet. Its dispersible dosage form must be suspended in water and administered under precise instructions. Generic developers would need to demonstrate pharmaceutical equivalence, bioequivalence where applicable, and acceptable product performance.
What is the Orange Book status of Carbaglu?
Carbaglu is an FDA-approved prescription drug and should be evaluated through the current Orange Book listing for its specific NDA and dosage form. Orange Book status can change as FDA accepts or delists patents, approves abbreviated new drug applications, or updates product records.
The commercial implications are:
- Listed patents, if any remain active, can trigger Paragraph IV certification.
- Expired patents do not prevent ANDA approval.
- Unlisted manufacturing know-how can still create development difficulty but cannot independently block an ANDA.
- Regulatory exclusivity must be analyzed separately from Orange Book patents.
A current Orange Book review is necessary before making a definitive statement about active listed patents or ANDA certification status.
When does Carbaglu lose exclusivity?
Carbaglu's original U.S. orphan exclusivity for NAGS deficiency ran for seven years from the 2010 approval. That period generally ended in 2017. The later organic-acidemia approval may have carried a separate period of regulatory protection depending on the specific supplement and indication, but that protection does not provide a permanent barrier to generic competition.
| Protection type |
Position |
| Original orphan exclusivity |
Expired after seven years from 2010 approval |
| Later indication exclusivity |
Must be assessed against the specific supplemental approval |
| Composition patent protection |
No widely recognized current barrier comparable to a new molecular entity |
| Formulation protection |
Possible, but product-specific and dependent on active patents |
| Data exclusivity |
Time-limited and distinct from patent protection |
| Market exclusivity |
No current orphan exclusivity should be assumed without a live FDA designation record |
The loss of exclusivity does not guarantee immediate generic entry. Ultra-rare products can remain commercially resilient because development economics are difficult, patient identification is specialized, and prescribers may be cautious about switching formulations.
Are generic companies challenging Carbaglu?
Publicly visible Paragraph IV litigation is not a defining part of Carbaglu's commercial history. The absence of prominent litigation does not prove that no ANDA applicant has pursued development. Generic activity can remain confidential until FDA approval, a patent certification notice, or litigation becomes public.
Potential generic barriers include:
- Small patient numbers that limit expected return on development investment.
- Difficulty recruiting suitable pharmacokinetic or clinical study populations.
- Specialized distribution and reimbursement requirements.
- Need to replicate the dispersible dosage form.
- Hospital and metabolic-center procurement practices.
- Limited commercial value from acute-use patients.
- Manufacturing controls for a high-purity metabolic product.
A first generic entrant could face limited competition if the market is too small to support several manufacturers. That dynamic can moderate price erosion even after approval.
What formulation patents and manufacturing barriers affect Carbaglu?
The formulation is commercially important because administration requires dispersing tablets in water. A generic product would need to match the labeled route and dosage form while maintaining stability, dissolution, dose uniformity, and acceptable handling characteristics.
Formulation and manufacturing risk
Carbaglu's principal technical barriers may include:
- Particle-size control for dispersion.
- Tablet disintegration and suspension uniformity.
- Stability after preparation.
- Packaging that protects the product from moisture.
- Scalable production of a specialized dosage form.
- Consistent supply to rare-disease treatment centers.
These factors can slow generic development but do not necessarily prevent it. Process patents, if active, would be narrower than a composition patent and could often be designed around.
How strong is the Carbaglu patent estate?
The patent estate is best characterized as moderate-to-weak for long-term exclusivity and stronger for commercial execution.
| Dimension |
Assessment |
| Active ingredient protection |
Weak or expired relative to newer medicines |
| Orphan exclusivity |
Expired for the original U.S. indication |
| Formulation complexity |
Moderate |
| Manufacturing know-how |
Moderate |
| Clinical differentiation in NAGS deficiency |
Strong |
| Generic substitution risk |
Moderate, rising over time |
| Biosimilar risk |
None |
| Switching risk |
Moderate because of specialty prescribing and dosage-form familiarity |
Clinical differentiation remains high in NAGS deficiency because carglumic acid addresses the underlying enzymatic activation defect. That does not translate into strong legal exclusivity, but it supports continued use where clinicians view the product as the most direct treatment option.
What companies compete with Carbaglu?
Carbaglu competes primarily with other ammonia-lowering treatments rather than with a direct pharmacologic substitute.
| Product or treatment |
Active ingredient or modality |
Relationship to Carbaglu |
| Buphenyl |
Sodium phenylbutyrate |
Nitrogen-scavenging alternative |
| Ravicti |
Glycerol phenylbutyrate |
Oral alternative for chronic urea-cycle management |
| Ammonul |
Sodium phenylacetate and sodium benzoate |
Hospital-based acute treatment |
| Hemodialysis or continuous renal replacement therapy |
Extracorporeal ammonia removal |
Acute rescue treatment |
| Nutritional management |
Protein restriction and specialized nutrition |
Adjunctive care |
| Liver transplantation |
Surgical intervention |
Rare, high-intensity alternative |
Carbaglu has the clearest product differentiation in NAGS deficiency. In organic acidemias, treatment decisions are more likely to depend on acute severity, institutional protocols, nutrition, dialysis availability, and use of other nitrogen scavengers.
What is the financial trajectory for Carbaglu?
Recordati does not generally disclose Carbaglu revenue as a standalone product line. Financial analysis therefore relies on segment reporting, portfolio commentary, prescription trends where available, and the product's underlying commercial structure.
The likely financial trajectory has four phases:
| Phase |
Financial characteristics |
| Launch and orphan uptake |
Low patient count, high price, specialist-center adoption |
| Expansion into organic acidemias |
Broader utilization and higher volume potential |
| Mature branded period |
Recurring NAGS revenue with episodic organic-acidemia demand |
| Post-exclusivity period |
Increasing generic risk, contracting pressure, and possible price erosion |
Revenue quality is comparatively attractive because NAGS patients may require chronic treatment. The addressable population is small, but annual revenue per treated patient can be substantial. Organic-acidemia use may add episodic demand without producing the same recurring revenue profile.
Main financial growth drivers
- Diagnosis of previously unrecognized NAGS deficiency.
- Improved referral to metabolic centers.
- Broader use in propionic acidemia and methylmalonic acidemia.
- Higher treatment persistence among diagnosed patients.
- Price increases or reimbursement expansion.
- International distribution through Recordati's rare-disease network.
Main financial risks
- Generic carglumic acid entry.
- Payer restrictions and prior authorization.
- Hospital substitution with other ammonia-lowering therapies.
- Treatment discontinuation after acute episodes.
- Small patient numbers and revenue concentration.
- Manufacturing interruptions.
- Dependence on specialist distribution.
Recordati's portfolio model can preserve commercial value even when an individual ultra-orphan product matures. The company has international infrastructure, regulatory expertise, and rare-disease sales capabilities that are difficult for a small generic entrant to replicate.
What licensing deals and ownership changes affect Carbaglu?
Carbaglu has been commercialized through the rare-disease businesses associated with Orphan Europe and Recordati. Recordati's acquisition and integration of rare-disease assets strengthened the product's international commercialization and distribution platform.
The strategic value of Carbaglu is not limited to unit sales. It contributes:
- Access to metabolic specialists.
- Relationships with rare-disease distributors.
- A platform for adjacent inborn-error-of-metabolism products.
- Portfolio breadth in ultra-orphan medicine.
- Regulatory and reimbursement infrastructure across multiple markets.
Public disclosures do not support treating Carbaglu as a major standalone revenue driver for Recordati. Its strategic value is greater as a stable portfolio asset than as a high-growth blockbuster.
What generic launch scenarios exist for Carbaglu?
Scenario 1: No near-term generic entry
Carbaglu retains strong pricing because the market is too small to attract multiple generic developers. This is the most favorable scenario for the branded product.
Scenario 2: One approved generic
A single generic enters, initially targeting high-volume or institutional accounts. Branded revenue declines through contracting and selective switching, while clinical use remains stable.
Scenario 3: Multiple generic entrants
Price erosion accelerates, especially in payer-controlled channels. The branded product may retain a niche among patients and physicians who prefer the established formulation or supply network.
Scenario 4: Formulation-specific competition
A competitor launches a product with a comparable dispersible dosage form but does not fully displace Carbaglu. Market share shifts gradually as payers test substitution.
The most probable economic pattern for a mature ultra-orphan small molecule is gradual erosion rather than the sharp collapse often seen in large primary-care markets. Patient numbers are too small for broad substitution campaigns, but a single generic can still pressure net pricing.
What is the geographic coverage of Carbaglu?
Carbaglu has been marketed across the United States and international markets through Recordati's rare-disease operations. Geographic performance depends on:
- National orphan-drug reimbursement.
- Availability of metabolic diagnostic testing.
- Hospital access to ammonia testing.
- Import and distribution rules.
- National pricing negotiations.
- Access to specialist physicians.
The United States is commercially important because orphan-drug pricing and specialty reimbursement can support high revenue per patient. European markets provide geographic diversification but may impose stronger price controls and centralized reimbursement negotiations.
Key Takeaways
- Carbaglu is an ultra-orphan carglumic acid product for NAGS deficiency and selected organic acidemias.
- Its strongest commercial asset is clinical differentiation in NAGS deficiency, not a long-lived patent barrier.
- Original U.S. orphan exclusivity from the 2010 approval has expired.
- Formulation complexity and specialized distribution may delay generic substitution but do not create permanent exclusivity.
- Biosimilar risk is not relevant because carglumic acid is a small molecule.
- Recordati does not generally report standalone Carbaglu revenue, limiting product-level financial modeling.
- Revenue should be viewed as mature, recurring rare-disease income with upside from diagnosis and organic-acidemia use.
- Generic entry would likely produce gradual price and share erosion, with severity determined by the number of approved competitors.
- NAGS deficiency supports durable utilization; organic-acidemia use adds volume but is more episodic.
- The product's strategic value is tied to Recordati's rare-disease commercial infrastructure and metabolic portfolio.
FAQs
Is Carbaglu a biologic drug?
No. Carbaglu contains carglumic acid, a synthetic small molecule. Biosimilar approval rules do not apply.
Can a generic company copy Carbaglu's dispersible tablets?
A generic applicant may seek approval if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and applicable patent certifications. The dispersible dosage form can increase development complexity.
Does Carbaglu have orphan-drug exclusivity today?
The original seven-year U.S. orphan exclusivity period for the 2010 NAGS deficiency approval expired. Any later indication-specific protection must be assessed against the applicable FDA approval record.
Is Carbaglu used for urea-cycle disorders other than NAGS deficiency?
Its primary disease-specific role is NAGS deficiency. Other urea-cycle disorders are generally managed with different nitrogen-scavenging strategies, nutritional treatment, and acute ammonia-lowering interventions.
Is Carbaglu revenue material to Recordati?
Carbaglu is strategically relevant within Recordati's rare-disease portfolio, but the company does not generally disclose the product's standalone revenue. Public reporting does not support treating it as one of Recordati's largest individual revenue products.
References
- U.S. Food and Drug Administration. (2010). Carbaglu: Prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Carbaglu (carglumic acid).
- U.S. Food and Drug Administration. (n.d.). Orphan Drug Designations and Approvals database.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- European Medicines Agency. (n.d.). Carbaglu: European public assessment report.
- Recordati S.p.A. (2023). Annual report and consolidated financial statements.
